CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RPL39P34 (ImmuneEditome ID:100271523)

1. Gene summary of enriched editing regions for RPL39P34

check button Gene summary
Gene informationGene symbol

RPL39P34

Gene ID

100271523

GeneSynonymsRPL39_15_1666
GeneCytomap

19q13.41

GeneTypepseudo
GeneDescription-
GeneModificationdate20230329
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:52561579-52568426:+ENST00000477141.1ENSG00000242255.1RPL39P34ncRNA_exonicHSMAR2,AluYk3,MER4A,AluSp,AluJr,AluJb,Alu,AluSx,AluSx3,(TA)n,AluSq2,MLT1A0,MER41D,(TTA)n,LTR24chr19:52561579-52568426:+.alignment


Top

2. Tumor-specific enriched editing regions for RPL39P34


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:52561579-52568426:+COADEER1.6121e-02image
chr19:52561579-52568426:+KICHEER7.6859e-04image
chr19:52561579-52568426:+STADEER4.0648e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:52561579-52568426:+KIRPCliEER1.1912e-027.3970e-030.2007image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for RPL39P34


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:52561579-52568426:+GBMEERENSG00000275877,5_8S_rRNA0.24273.6798e-035.8242e-080.4524imageNNNAMacrophages_M1GSVA_HALLMARK_HEME_METABOLISM
chr19:52561579-52568426:+GBMEERENSG00000201098,RNY10.34914.3472e-031.0487e-090.5015imageNNNAMacrophages_M1GSVA_HALLMARK_APICAL_JUNCTION
chr19:52561579-52568426:+GBMEERENSG00000280614,CH507-513H4.40.27341.8595e-029.5545e-090.4754imageNNNAMacrophages_M1GSVA_HALLMARK_HEME_METABOLISM
chr19:52561579-52568426:+GBMEERENSG00000200795,RNU4-10.29802.1869e-021.6538e-080.4686imageNNNAMacrophages_M1GSVA_HALLMARK_HEME_METABOLISM
chr19:52561579-52568426:+GBMEERENSG00000202538,RNU4-20.28463.3245e-021.0385e-080.4744imageNNNAMacrophages_M1GSVA_HALLMARK_HEME_METABOLISM
chr19:52561579-52568426:+UCECEERENSG00000024422,EHD20.30721.5310e-026.8485e-120.5139imageNADAR;CPSF6;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28A;LIN28B;LSM11;NOP56;NOP58;PRPF8;RBFOX2;RBM27;SLTM;SND1;SRSF1;SRSF7;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1EHD2T_cells_CD8GSVA_HALLMARK_MYOGENESIS
chr19:52561579-52568426:+UCECEERENSG00000139567,ACVRL10.29482.1502e-024.6125e-080.4205imageNADAR;CPSF6;CSTF2T;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP2;LIN28A;MOV10;NOP56;NOP58;PRPF8;QKI;RBFOX2;RBM27;SND1;TAF15;TARDBP;U2AF2;UPF1;XRN2ACVRL1T_cells_regulatory_(Tregs)GSVA_HALLMARK_MYOGENESIS
chr19:52561579-52568426:+DLBCEERENSG00000023041,ZDHHC6-0.66241.5884e-022.3362e-05-0.6290imageNADAR;BUD13;CNBP;CPSF6;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS3;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;QKI;RBFOX2;RBM10;RBM47;SF3A3;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;XRN2NANK_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:52561579-52568426:+DLBCEERENSG00000206754,SNORD101-0.64581.6426e-021.4122e-04-0.5787imageNNNANK_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:52561579-52568426:+DLBCEERENSG00000256073,URB1-AS10.67841.6912e-027.3684e-060.6573imageNCNBP;DDX54;ELAVL1;FBL;FMR1;IGF2BP2;KHDRBS3;LIN28B;MOV10;NOP56;NOP58;RBFOX2;UPF1;YTHDF1NANeutrophilsGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for RPL39P34


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:52561579-52568426:+
ESCAEERESENSG00000135164.14chr787166482:87166605:87167956:87168043:87170994:87171017-0.44968.5347e-054.5385e-08-0.4421imageNADAR;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS3;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;QKI;RBFOX2;RBM10;RBM27;RBM47;SF3A3;SLTM;SND1;SRSF1;SRSF7;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZC3H7BNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr19:52561579-52568426:+
ESCAEERMEXENSG00000026508.12chr1135190009:35190065:35198120:35198246:35211263:35211449:35214851:352148610.35691.6259e-027.5360e-070.4051imageNADAR;CNBP;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28A;LIN28B;MOV10;NOP56;NOP58;RBFOX2;RBM27;RBM47;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF2;UPF1;YTHDF1CD44B_cells_naiveGSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:52561579-52568426:+
ESCAEERA5ENSG00000137501.12chr1185709466:85709500:85714412:85714449:85711112:857144490.29953.7047e-023.4345e-060.4245imageNADAR;CNBP;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;RBM10;TAF15;TARDBP;TROVE2;U2AF2;UPF1;ZC3H7BSYTL2Macrophages_M1GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr19:52561579-52568426:+
ESCAEERIRENSG00000050426.11chr1251048300:51049185:51056349:51056391-0.43071.7612e-035.8070e-07-0.4075imageNADAR;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS3;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;QKI;RBFOX2;RBM10;RBM27;RBM47;SF3A3;SLTM;SND1;SRSF1;SRSF7;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZC3H7BNAGSVA_HALLMARK_UV_RESPONSE_UP
chr19:52561579-52568426:+
ESCAEERMEXENSG00000026508.12chr1135189834:35190065:35198120:35198246:35209964:35211449:35214851:352148610.35381.8119e-027.8651e-070.4045imageNADAR;CNBP;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28A;LIN28B;MOV10;NOP56;NOP58;RBFOX2;RBM27;RBM47;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF2;UPF1;YTHDF1CD44B_cells_naiveGSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:52561579-52568426:+
ESCAEERIRENSG00000151914.13chr656463564:56463764:56464684:56464756-0.34177.8989e-033.2551e-06-0.4290imageNADAR;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS3;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;QKI;RBFOX2;RBM10;RBM27;RBM47;SF3A3;SLTM;SND1;SRSF1;SRSF7;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZC3H7BDSTDendritic_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:52561579-52568426:+
ESCAEERIRENSG00000141568.15chr1782593421:82600244:82601302:82601530-0.30172.2674e-024.7704e-05-0.4007imageNADAR;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS3;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;QKI;RBFOX2;RBM10;RBM27;RBM47;SF3A3;SLTM;SND1;SRSF1;SRSF7;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZC3H7BFOXK2T_cells_CD4_memory_restingGSVA_HALLMARK_P53_PATHWAY
chr19:52561579-52568426:+
ESCAEERESENSG00000135540.7chr6138433507:138433680:138441982:138442114:138447000:138447193-0.38912.8528e-036.1888e-07-0.4208imageNADAR;AUH;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS3;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;QKI;RBFOX2;RBM10;SF3A3;SLTM;SND1;SRSF1;SRSF7;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;ZC3H7BNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52561579-52568426:+
GBMEERIRENSG00000188747.4chr9137433964:137434079:137434223:137434405-0.33636.0500e-039.1700e-06-0.4198imageNAUH;CPSF6;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;KHDRBS1;LIN28B;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;XRN2NOXA1NK_cells_restingGSVA_HALLMARK_ADIPOGENESIS
chr19:52561579-52568426:+
GBMEERIRENSG00000125901.5chr203046613:3046900:3047734:3048254-0.29572.5350e-021.1227e-05-0.4217imageNAUH;BUD13;CNBP;CPSF6;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;RBM27;SF3A3;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZC3H7BNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

5. Enriched editing regions and immune infiltration for RPL39P34


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:52561579-52568426:+ACCEERMast_cells_resting1.5328e-030.3910image
chr19:52561579-52568426:+BLCAEERMacrophages_M24.6678e-030.1583image
chr19:52561579-52568426:+BRCAEERMast_cells_resting3.2383e-020.0679image
chr19:52561579-52568426:+CESCEERDendritic_cells_activated3.2034e-02-0.1473image
chr19:52561579-52568426:+COADEERB_cells_naive3.9839e-020.1413image
chr19:52561579-52568426:+DLBCEERNK_cells_activated8.3072e-030.4220image
chr19:52561579-52568426:+ESCAEERT_cells_CD4_memory_resting1.6780e-03-0.2632image
chr19:52561579-52568426:+GBMEERT_cells_regulatory_(Tregs)3.0971e-02-0.1886image
chr19:52561579-52568426:+KIRPEERMacrophages_M13.4738e-040.2198image
chr19:52561579-52568426:+LAMLEERT_cells_CD84.9697e-020.1605image
chr19:52561579-52568426:+LGGEERDendritic_cells_activated3.5901e-020.1105image
chr19:52561579-52568426:+LIHCEERMast_cells_resting1.3211e-020.2335image
chr19:52561579-52568426:+LUADEEREosinophils1.6190e-030.1593image
chr19:52561579-52568426:+LUSCEERNK_cells_activated2.3487e-02-0.1247image
chr19:52561579-52568426:+MESOEERMacrophages_M11.9397e-020.2850image
chr19:52561579-52568426:+OVEERT_cells_CD89.3325e-050.2338image
chr19:52561579-52568426:+PCPGEERMacrophages_M12.8326e-020.1729image
chr19:52561579-52568426:+PRADEERMast_cells_resting2.4512e-020.1028image
chr19:52561579-52568426:+SARCEERMonocytes3.2095e-02-0.1487image
chr19:52561579-52568426:+SKCMEERMacrophages_M13.9857e-02-0.1222image
chr19:52561579-52568426:+STADEERT_cells_CD4_memory_activated1.5433e-030.1791image
chr19:52561579-52568426:+TGCTEERT_cells_CD4_memory_resting2.9206e-060.3655image
chr19:52561579-52568426:+THCAEERT_cells_CD4_memory_activated4.0627e-050.1826image
chr19:52561579-52568426:+THYMEERDendritic_cells_activated1.1302e-020.2355image
chr19:52561579-52568426:+UCSEERT_cells_CD4_memory_activated1.2376e-020.3584image


Top

6. Enriched editing regions and immune gene sets for RPL39P34


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr19:52561579-52568426:+KIRPEER1.0310e-02image9.3065e-070.2982image
chr19:52561579-52568426:+THCAEER4.8315e-02image2.8825e-030.1331image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:52561579-52568426:+ACCGSVA_HALLMARK_G2M_CHECKPOINTEER4.7453e-02-0.2508image
chr19:52561579-52568426:+BLCAGSVA_HALLMARK_MYOGENESISEER1.7521e-030.1748image
chr19:52561579-52568426:+BRCAGSVA_HALLMARK_HYPOXIAEER5.8307e-060.1432image
chr19:52561579-52568426:+CHOLGSVA_HALLMARK_UV_RESPONSE_DNEER3.1232e-020.3876image
chr19:52561579-52568426:+COADGSVA_HALLMARK_ANDROGEN_RESPONSEEER7.4871e-040.2298image
chr19:52561579-52568426:+DLBCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.8039e-020.3817image
chr19:52561579-52568426:+ESCAGSVA_HALLMARK_MYOGENESISEER2.9189e-050.3454image
chr19:52561579-52568426:+KIRCGSVA_HALLMARK_GLYCOLYSISEER1.1914e-080.2956image
chr19:52561579-52568426:+KIRPGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER9.3065e-070.2982image
chr19:52561579-52568426:+LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.7309e-020.1622image
chr19:52561579-52568426:+LGGGSVA_HALLMARK_NOTCH_SIGNALINGEER4.9080e-03-0.1478image
chr19:52561579-52568426:+LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER9.6864e-030.1422image
chr19:52561579-52568426:+OVGSVA_HALLMARK_MITOTIC_SPINDLEEER3.6920e-05-0.2465image
chr19:52561579-52568426:+PCPGGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.8212e-020.1730image
chr19:52561579-52568426:+PRADGSVA_HALLMARK_ADIPOGENESISEER6.4396e-040.1554image
chr19:52561579-52568426:+READGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.8042e-02-0.2291image
chr19:52561579-52568426:+SARCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.8676e-020.1517image
chr19:52561579-52568426:+SKCMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER5.1671e-030.1658image
chr19:52561579-52568426:+STADGSVA_HALLMARK_HYPOXIAEER2.0066e-100.3511image
chr19:52561579-52568426:+TGCTGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.5757e-11-0.4998image
chr19:52561579-52568426:+THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.5509e-050.1840image
chr19:52561579-52568426:+THYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER6.0835e-030.2544image
chr19:52561579-52568426:+UCECGSVA_HALLMARK_MYOGENESISEER2.9344e-030.2367image
chr19:52561579-52568426:+UCSGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.3521e-020.3265image
chr19:52561579-52568426:+UVMGSVA_HALLMARK_MYOGENESISEER1.5926e-030.5072image


Top

7. Enriched editing regions and drugs for RPL39P34


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:52561579-52568426:+ACCJNK.Inhibitor.VIIIEER3.6608e-020.2639image
chr19:52561579-52568426:+BLCACGP.60474EER2.0977e-04-0.2064image
chr19:52561579-52568426:+BRCABIRB.0796EER2.6001e-040.1157image
chr19:52561579-52568426:+CESCGDC.0449EER4.6533e-02-0.1369image
chr19:52561579-52568426:+CHOLMethotrexateEER3.2054e-02-0.3922image
chr19:52561579-52568426:+COADGSK.650394EER1.1035e-020.1742image
chr19:52561579-52568426:+DLBCMethotrexateEER4.3076e-050.6197image
chr19:52561579-52568426:+ESCAGNF.2EER1.6927e-05-0.3549image
chr19:52561579-52568426:+GBMErlotinibEER6.2415e-03-0.2378image
chr19:52561579-52568426:+HNSCBX.795EER2.9032e-050.3271image
chr19:52561579-52568426:+KICHA.443654EER7.3087e-040.4115image
chr19:52561579-52568426:+KIRCGNF.2EER3.6759e-04-0.1873image
chr19:52561579-52568426:+KIRPBX.795EER1.6378e-05-0.2633image
chr19:52561579-52568426:+LAMLBMS.509744EER3.7929e-02-0.1697image
chr19:52561579-52568426:+LGGMidostaurinEER2.2385e-030.1604image
chr19:52561579-52568426:+LUADCytarabineEER1.8676e-020.1192image
chr19:52561579-52568426:+LUSCKU.55933EER1.7632e-02-0.1306image
chr19:52561579-52568426:+OVAZ628EER1.0230e-05-0.2630image
chr19:52561579-52568426:+PRADFTI.277EER1.5253e-020.1108image
chr19:52561579-52568426:+READBicalutamideEER5.7270e-03-0.3161image
chr19:52561579-52568426:+SARCMetforminEER3.4944e-030.2016image
chr19:52561579-52568426:+SKCMBIBW2992EER2.8716e-05-0.2459image
chr19:52561579-52568426:+STADAZ628EER5.6752e-07-0.2795image
chr19:52561579-52568426:+TGCTLFM.A13EER2.6214e-13-0.5438image
chr19:52561579-52568426:+THCABMS.708163EER1.6681e-07-0.2316image
chr19:52561579-52568426:+THYMGSK269962AEER5.7592e-040.3162image
chr19:52561579-52568426:+UCECGW.441756EER1.3666e-070.4068image
chr19:52561579-52568426:+UCSAZD6244EER3.8980e-02-0.2990image
chr19:52561579-52568426:+UVMMethotrexateEER7.2277e-030.4401image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType